This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Managing and Reducing CV Risk in T2DM: An Online E-Forum

Managing and Reducing CV Risk in T2DM: An Online E-Forum

Format

Interactive Monograph

Time to Complete

30 minutes

Released

January 19, 2017

Expires

January 19, 2018
Add to Queue


Maximum Credits

0.50 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by Forefront Collaborative

Commercial Supporter

This online E-Forum is supported by independent educational grants from Novo Nordisk US, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Program Description

The management of cardiovascular risk in patients with type 2 diabetes continues to evolve with changing guidelines and emerging data. This online e-forum will provide the most frequently asked questions and answers from education on the evidence-based recommendations for management of cardiovascular risk in patients with type 2 diabetes. It will also provide the latest data on the long-term cardiovascular outcomes associated with the newest medications to treat type 2 diabetes, including incretin therapies and sodium glucose transporter-2 inhibitors. Participants will also have access to an online lecture that provides baseline information on these topics. For the past three months, participants have submitted questions that have been answered by the expert faculty.

Intended Audience

The target audience for this educational activity is endocrinologists, cardiologists, primary care clinicians, and other healthcare providers who treat patients and are interested in the primary prevention of cardiovascular disease in patients with diabetes.

Educational Objective

As a result of participating in this educational intervention, participants should be able to summarize commonly asked questions related to the management of patients with diabetes and cardiovascular disease and/or multiple cardiovascular risk factors.

Conflict Of Interest Disclosure Policy

Educational activities provided by Forefront Collaborative must demonstrate balance, independence, and scientific rigor. All those in a position to control the content of an activity must disclose all relevant financial relationship(s) with commercial interest(s).* For this educational activity, all conflicts of interest have been resolved through peer review and revisions to ensure independence, evidence base, fair balance, and absence of commercial bias. Disclosures appear below.

*The ACCME defines a commercial interest as any entity producing, marketing, reselling, or distributing healthcare goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Faculty

Harold Bays, MD, FTOS, FACC, FACE, FNLA
Medical Director and President,
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Dr. Bays has received research grants from: Amarin Corporation, Amgen, Ardea Biosciences, Arisaph Pharmaceuticals, AstraZeneca, Bristol-Meyers Squibb, Catabasis Pharmaceuticals, CymaBayTherapeutics, Eisai, Elcelyx Therapeutics, Eli Lilly and Company, Esperion Therapeutics, Ferrer/Chiltern International, Gilead Sciences, GlaxoSmithKline, Hanmi Pharmaceutical, Hisun USA, Home Access Health Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Kowa American Corporation, Merck & Co., Necktar, Novartis, Novo Nordisk, Omthera Pharmaceuticals, Orexigen Therapeutics, Pfizer, ProNova Solutions, Regeneron Pharmaceuticals, Roche, Sanofi, Takeda Pharmaceuticals U.S.A., and TimPharma LLC. He has consulted for: Alnylam Pharmaceuticals, Akcea Therapeutics, Amgen, AstraZeneca, Eli Lilly and Company, Ionis Pharmaceuticals (ISIS), Janssen Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Moderna Therapeutics, Novartis, Procter & Gamble, ProNova Solutions, Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceuticals U.S.A. He has also been a speaker for: Amarin Corporation, Amgen, AstraZeneca, Eisai, Regeneron Pharmaceuticals, Sanofi, and Takeda Pharmaceuticals U.S.A.

Lawrence Blonde, MD, FACP, MACE
Director, Ochsner Diabetes Clinical Research Unit
Frank Riddick Diabetes Institute
Department of Endocrinology
Ochsner Medical Center
New Orleans, LA

Dr. Blonde has consulted for: AstraZeneca, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi. He has been a part of the speaker’s bureau for: AstraZeneca, Janssen Pharmaceuticals, Inc., Novo Nordisk, and Sanofi. He has received grant and research support from: AstraZeneca, Janssen Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk, and Sanofi.

Yehuda Handelsman, MD, FACP, FACE, FNLA
Medical Director and Principal Investigator,
Metabolic Institute of America
Tarzana, CA

Dr. Handelsman has received research grants from: Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Esperion, Grifols, Hanmi Pharmaceutical, Intarcia Therapeutics, Inc., GlaxoSmithKline, Lexicon Pharmaceuticals, Inc., Merck & Co., Novo Nordisk, and Sanofi. He has consulted for: Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Merck & Co., Novo Nordisk, Regeneron Pharmaceuticals, Inc., and Sanofi. He has been a part of the speaker’s bureau for: Amarin Corporation, Amgen, AstraZeneca, Boehringer Ingelheim-Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Novo Nordisk, Regeneron Pharmaceuticals, Inc., and Sanofi. He was the IP President of the American College of Endrocrinology. He was the editor of the Journal of Diabetes.

CME Content Review

The content of this activity was independently peer reviewed. The reviewers of this activity have no relevant financial relationships to disclose.

Accredited Provider Disclosure

Christine Tebben and Stephanie Breslan, MS, of Forefront Collaborative have no financial relationships to disclose relative to the content of this CME activity.

Credit

0.50

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Forefront Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Forefront Collaborative designates this online enduring E-forum for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity includes discussion of off-label uses of drugs.

Disclaimer

The views and opinions expressed in this activity are those of the faculty and do not necessarily reflect the views or recommendations of Forefront Collaborative.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please review the activity materials and respond to the post-test and evaluation. You will receive a digital copy of your credit certificate once you have successfully completed this program. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue